Please assess the completion status of the following clinical trial:

Trial Title: 12 / 48 Week Pivotal PFT vs PBO in COPD I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* All patients must have a diagnosis of chronic obstructive pulmonary disease~* Male or female patients, 40 years of age or older Patients must be current or ex-smokers with a smoking history of more than 10 pack years Post bronchodilator FEV1 \<80% predicted and post-bronchodilator FEV1/FVC \<70%~Exclusion criteria:~* Patients with a significant disease other than COPD~* Patients with a history of asthma~* Patients with any of the following conditions:~a history of myocardial infarction within 1 year of screening visit (Visit 1) unstable or life-threatening cardiac arrhythmia. have been hospitalized for heart failure within the past year. known active tuberculosis a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed) a history of life-threatening pulmonary obstruction a history of cystic fibrosis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olodaterol (BI 1744) Low (Type: EXPERIMENTAL): Low dose inhaled orally once daily from the Respimat inhaler
- Olodaterol (BI 1744) High (Type: EXPERIMENTAL): High dose inhaled orally once daily from the Respimat inhaler
- Placebo (Type: PLACEBO_COMPARATOR): Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).